Adenosine News and Research

RSS

Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a ß-N9-glycosidic bond.

Discovery could be used to prevent viral infection and autoimmunity

Researchers have discovered that chemical changes to mRNA regulate the production of interferon beta, and hope to exploit this in new treatments.

27 Nov 2018

CRISPR-based tool shown to enhance cell-based immunotherapy

Researchers have developed a CRISPR-based tool called SLICE that can boost the effectiveness of immune cell therapies.

15 Nov 2018

New discovery may unlock development of next-generation sleeping pill

Insomnia is one of the major sleep problems with an estimated prevalence of 10% to 15% in the general population and 30% to 60% in the older population. Moreover, insomnia frequently co-occurs with a wide range of psychiatric disorders, including depression and anorexia.

26 Oct 2018

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.

23 Oct 2018

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.

8 Oct 2018

Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.

7 Oct 2018

Metabolic dysfunction drives chronic illness

Much of modern Western medicine is based upon the treatment of acute, immediate harm, from physical injury to infections, from broken bones and the common cold to heart and asthma attacks.

7 Sep 2018

Lymph node structural cells exert control over T cell responses

Until now, the study of the immune system has focused almost exclusively on white blood cells, and T cells in particular, as the body’s major infection fighters.

6 Sep 2018

New LSU research aims to prevent kidney failure caused by type 2 diabetes

A National Institutes of Health grant will help LSU Pennington Biomedical Research Center take the next step to better understanding how to prevent the kidney damage and failure caused by type 2 diabetes.

6 Sep 2018

Study reveals RNA editing regulator involved in cancer development

Researchers have discovered a bidirectional regulator of adenosine-to-inosine (A-to-I) RNA editing that could serve as a new cancer drug target.

21 Aug 2018

NUS study discovers a bidirectional regulator and shines light on A-to-I RNA editing in cancer cells

An in-depth study on the regulation of adenosine-to-inosine (A-to-I) RNA editing by researchers from the Cancer Science Institute of Singapore at the National University of Singapore found that a protein, known as DHX9, acts as a bidirectional regulator of the molecular process which is linked to various types of cancer such as esophageal cancer.

17 Aug 2018

Defects in RNA modification can cause altered smooth muscle contraction

Genetic information is stored in DNA and is passed on in a very stable manner from one cell to the next or from one generation to the next.

9 Aug 2018

Researchers develop artificial enzymes that drive reactions on living cells

Nature has evolved thousands of enzymes to facilitate the many chemical reactions that take place inside organisms to sustain life.

26 Jul 2018

Drug in clinical trials for Parkinson's disease offers hope for treating heart failure

A drug currently in clinical trials for treating symptoms of Parkinson's disease may someday have value for treating heart failure, according to results of early animal studies by Johns Hopkins Medicine researchers.

20 Jul 2018

Can-Fite BioPharma receives Australian and Chinese patents for new drug to treat erectile dysfunction

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."

17 Jul 2018

Research sheds on how new species may arise from rapid mitochondrial evolution

Genetic research at Oregon State University has shed new light on how isolated populations of the same species evolve toward reproductive incompatibility and thus become separate species.

13 Jul 2018

U.S. researchers recommend development of anti-cancer drugs based on mechanism of Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.

2 Jul 2018

Study describes new mechanism involved in memory loss associated with aging

A study led by Luísa Lopes, Group Leader at Instituto de Medicina Molecular João Lobo Antunes and published today in the prestigious journal Molecular Psychiatry, describes a new mechanism involved in memory loss associated with aging.

28 Jun 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

Sleep deprivation study to pinpoint brain processes causing poor decision-making

Sleep deprivation can take a heavy toll on our ability to make sound decisions, with potentially disastrous outcomes.

17 May 2018